H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Relay Therapeutics to $43 from $50 and keeps a Buy rating on the shares post the Q3 results.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RLAY:
- Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
- Relay Therapeutics to Announce Third Quarter 2022 Financial Results and Corporate Highlights
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Relay Therapeutics initiated with an Equal Weight at Barclays
- Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Precision Oncology Conference